Gainers
- Atreca BCEL shares rose 45.6% to $0.34 during Thursday's after-market session. The market value of their outstanding shares is at $13.4 million.
- Evoke Pharma EVOK shares moved upwards by 16.45% to $0.99. The market value of their outstanding shares is at $3.3 million.
- INVO Bioscience INVO stock increased by 10.57% to $1.15. The market value of their outstanding shares is at $2.8 million.
- Avenue Therapeutics ATXI shares rose 9.25% to $0.19. The company's market cap stands at $2.5 million.
- Sunshine Biopharma SBFM stock moved upwards by 6.82% to $0.26. The company's market cap stands at $6.7 million.
- Monopar Therapeutics MNPR shares increased by 6.22% to $0.47. The market value of their outstanding shares is at $6.9 million.
Losers
- HeartBeam BEAT shares decreased by 6.9% to $1.63 during Thursday's after-market session. The market value of their outstanding shares is at $42.9 million.
- Alaunos Therapeutics TCRT shares declined by 6.74% to $0.13. The company's market cap stands at $31.6 million.
- Sagimet Biosciences SGMT stock declined by 5.62% to $6.72. The market value of their outstanding shares is at $153.8 million.
- Rapid Micro Biosystems RPID stock declined by 5.25% to $0.9. The market value of their outstanding shares is at $38.1 million.
- Unicycive Therapeutics UNCY stock fell 5.0% to $0.89. The market value of their outstanding shares is at $30.9 million.
- 180 Life Sciences ATNF stock fell 4.96% to $0.21. The company's market cap stands at $2.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
ATXIAvenue Therapeutics Inc
$1.70-3.95%
BCELAtreca Inc Class A
$0.0900-%
BEATHeartBeam Inc
$2.39-1.65%
EVOKEvoke Pharma Inc
$4.95-2.37%
MNPRMonopar Therapeutics Inc
$26.562.87%
RPIDRapid Micro Biosystems Inc
$0.96016.68%
SBFMSunshine Biopharma Inc
$2.790.36%
SGMTSagimet Biosciences Inc
$4.91-0.81%
TCRTAlaunos Therapeutics Inc
$1.981.02%
UNCYUnicycive Therapeutics Inc
$0.6801-0.57%
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in